---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Natural history, survival, and mortality"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Natural history, survival, and mortality. Topics: Natural history: age at regression and onset of hand stereotypies; Natural history: trajectory of skill gain, loss, and regain; Natural history: course in women aged 40 years and older; Survival: North American database of 1928 individuals; 6 further topics. 10 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Natural history: age at regression and onset of hand stereotypies

> “Age at onset of regression (Table 1A) occurred between 12 and 30 months in more than 80% of individuals, with 36.2% occurring between 12 and 18 months of age and 46.1% between 18 and 30 months.”
> “Stereotypies (Table 1B) began most frequently (55.6%) at 18–36 months, whereas 22.7% developed these from 12 to 18 months.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

> “Developmental regression occurred in all Rett syndrome participants (median 18 months)”

Source: [Cutri-French et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8882337/)

<a id="topic-2.2.1.3-2"></a>

### Natural history: trajectory of skill gain, loss, and regain

> “Loss of previously gained skills occurred in all skill domains, with highest frequency in fine motor and expressive language domains. For most skills, loss occurred early in life and within 2 years of gain, except for loss of gross motor skills which occurred at older ages and further from age of gain. Regain of lost skills was infrequent for most skills, occurred mainly before 6 years old, and within 2 years of loss. After 6 years old, the incidence of either gaining or regaining skills was low.”
> “The median age of skill loss was 3 years old or less for 46 of the 51 developmental skills (90%), and in 31 developmental skills, 95% of participants lost skills by 6 years old.”
> “After age 6 years it is unlikely that a skill not previously obtained will be gained or that a skill previously lost will be regained.”

Source: [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/)

<a id="topic-2.2.1.3-3"></a>

### Natural history: course in women aged 40 years and older

> “Information was available on 30 women with a clinical diagnosis of Rett syndrome (RTT), of whom 24 were < 50 years. Twenty‐nine women were diagnosed with classic RTT and one with atypical RTT. Of 18 women tested for MECP2 mutations, pathogenic variants were identified in 14. There was little increase in severity over time.”
> “Some features of RTT improved with aging, for example, epilepsy, agitation, sleep, and hand stereotypies.”

Source: [Hryniewiecka-Jaworska et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11975466/)

<a id="topic-2.2.1.3-4"></a>

### Survival: North American database of 1928 individuals

> “Earlier decennial cohorts had better survival than recent cohorts, most participants surviving into middle age. Comparing overall survival between typical and atypical RTT, those with typical RTT had greater mortality than those with atypical RTT across the observed lifespan (p<.0001).”
> “Among all participants studied, a total of 305 deaths (15.8%) had occurred as of January 1, 2006.”

Source: [Kirby et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2794941/)

<a id="topic-2.2.1.3-5"></a>

### Survival: US Rett Syndrome Natural History Study

> “Among 1189 valid participants, 51 died (range 3.9–66.6 years) during the 9-year follow-up period.”
> “Survival for classic and atypical RTT was greater than 70% at 45 years.”
> “We can estimate, with 95% confidence, that at least 95% of the classic RTT population survive until age 20, 80% survive until age 35, and over 70% survive until age 50.”

Source: [Tarquinio et al. (2015b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4609589/)

<a id="topic-2.2.1.3-6"></a>

### Survival: Australian Rett Syndrome Database, 20 years of follow-up

> “Using the Kaplan-Meier method, we estimated survival of individuals registered with the Australian Rett syndrome Database (ARSD) who had been followed for up to 20 years (n = 396).”
> “The conditional probability of survival was 77.6% (95% confidence interval (CI) 71.3, 82.8) at 20 years, 71.5% (95% CI 64.6, 77.3) at 25 years and 59.8% (95% CI 49.3,68.8) at 37 years (Figure 1).”

Source: [Anderson et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4078387/)

<a id="topic-2.2.1.3-7"></a>

### Survival: Rett's original Austrian cohort compared with the Australian database

> “The median age at death was 13 years 4.8 months. The probability of survival up to the age of 25 years was 21%, compared with 71% in the Australian cohort (p<0.001).”

Source: [Freilinger et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20573179/)

<a id="topic-2.2.1.3-8"></a>

### Causes of death

> “Most deaths were due to cardiorespiratory issues. Only one died due to severe malnutrition, scoliosis, and extreme frailty.”
> “Post-operative complications were a cause of death in a minority, following scoliosis surgery, ileostomy, and tonsillectomy. Epilepsy was cited as cause of death (without respiratory complications) in four classic RTT participants and one atypical RTT participant.”

Source: [Tarquinio et al. (2015b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4609589/)

> “Information on cause of death was available for 57 (82.6%) out of 69 females who were deceased. Lower respiratory tract infection (36.8% 21/57) was the most common cause of death, followed by aspiration/asphyxiation (31.6% 18/57), respiratory failure (14.0% 8/57) and seizure related illness (5.3% 3/57).”

Source: [Anderson et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4078387/)

<a id="topic-2.2.1.3-9"></a>

### Sudden death: cardiorespiratory and autonomic risk factors

> “Notably, cardiorespiratory dysfunction may account for 26% to 47% of sudden, unexpected Rett syndrome-associated deaths.”

Source: [Tarquinio et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6026556/)

> “Following a review of the articles relating to sudden death, we identified reduced heart rate variability, epilepsy and deleterious changes in cardiac repolarization (QT prolongation and T-wave changes) as potential risk factors for sudden death.”

Source: [Singh et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7828978/)

<a id="topic-2.2.1.3-10"></a>

### Risk factors for mortality: severity, ambulation, weight, seizures, and genotype

> “For classic RTT, several variables, such as ambulation, frequent seizures, frequent hospitalizations and illness, microcephaly and low weight, were independently associated with higher odds of mortality using a Cox proportional hazard model (Table 4).”
> “However, the majority of those who died (54%, or 19/35) weighed less than the 25th percentile on the Rett-specific charts, compared to 22% of those who survived (p < .001).”

Source: [Tarquinio et al. (2015b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4609589/)

> “Using the Cox proportional hazard model, those with large deletions had, at any time during the observation period, slightly more than 3 times (HR 3.11, 95% CI 0.60, 16.10) the risk of death than those with the p.Arg133Cys mutation.”

Source: [Anderson et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4078387/)

Additional sources: [ClinicalTrials.gov NCT00299312](https://clinicaltrials.gov/study/NCT00299312); [ClinicalTrials.gov NCT02738281](https://clinicaltrials.gov/study/NCT02738281)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
